The Column Group — 2015 Investments
4 investments dated 2015 · listed companies and verified rows first · show all
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)
Board seatPeter SvennilsonDavid Goeddel· per SEC Form D · $100M raise · filed Apr 2018
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThird Rock Ventures
BiotechBurlingame, US
John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)
BoardJohn Diekman(Director)inCarl Gordon(Director)inRobert Schreiber(Director)
Board seatDavid Goeddel· per SEC Form D · $6.3M raise · filed Jan 2015
Co-investors5AM VenturesOrbiMed
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)Kenneth Clark(Executive Officer)
BoardTerry McGuire(Director)inJoshua Wolfe(Director)in
Board seatTim Kutzkey· per SEC Form D
Co-investorsDns CapitalIllumina VenturesLux CapitalPolaris Partners
Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)
BoardMark Goldsmith(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalSofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.